Purpose of Review Liver disease is an important clinical and global problem and is the 16th leading cause of death worldwide and responsible for 1 million deaths worldwide each year. Infectious disease is a major cause of liver disease specifically and overall is even a greater cause of patient morbidity and mortality. Tools to study human liver disease and infectious disease have been lacking which has significantly hampered the study of liver disease generally and hepatotropic pathogens more specifically. Historically, hepatoma cell lines have been used for in vitro cell culture models to study infectious disease. Significant differences between human hepatoma cell lines and the human hepatocyte has hampered our understanding of hepatocyte pathogen infection and hepatocyte--pathogen interactions. Recent Findings Despite these limitations, great progress was made in the understanding of specific aspects of the life cycle of the canonical hepatocyte viral pathogen, Hepatitis C Virus. Over time various specific drugs targeting various proteins of the HCV virion or aspects of the HCV viral life cycle have been created that enable almost complete elimination of the virus in vitro and clinically. These drugs, direct-acting antivirals have enabled achieving sustained virologic response in over 90-95 percent of patients. Summary Despite the development of direct-acting antivirals and the extreme success in achieving sustained virologic response, there has only been limited success elucidating host-pathogen interactions largely due to the poor nature of the hepatoma platform. Alternative approaches are needed. Pluripotent stem cells are renewable, can be derived from a single donor and can be efficiently and reproducibly differentiated towards many cell types including ectodermal-, endodermal-, and mesodermal-derived lineages. The development of pluripotent stem cell-derived hepatocyte-like cells (iHLCS) changes the paradigm as robust cells with the phenotype and function of hepatocytes can be readily created on demand with a variety of genetic background or alterations. iHLCs are readily used as models to study human drug metabolism, human liver disease, and human hepatotropic infectious disease. In this review, we discuss the biology of the HCV virus, the use of iHLCs as models to study human liver disease, and review the current work on using iHLCs to study HCV infection.
Introduction
Infectious diseases are a major public health concern as the second leading cause of death and responsible for one-fifth of deaths worldwide [1] . Currently, the strategy to treat infectious diseases is based on therapies targeting the infectious agent but this approach over time through evolutionary pressure and selection has led to the emergence of multidrug resistance and thus reduced pathogen susceptibility. Therefore, an improved understanding of hostpathogen interactions and response leading to the identification of the host factors involved in host-pathogen susceptibility and resistance is crucial to understanding and impacting disease pathogenesis. Improved knowledge of these host factors will enable the development of clinical therapies based on enhancing host immune response or altering host susceptibility and resistance (rather than through targeting the pathogen which leads to pathogen resistance over time). More specifically, the host immune response to viral infections is characterized by various independent components; physical barriers, innate immunity, and cellular immunity [2, 3] . The innate immunity in particular has both soluble and cellular components all of which have been demonstrated to be upregulated early after initial viral infection. Innate immunity is driven by host genetic factors and their impact on viral infection has been shown to be key regulators of viral infection. Many of these approaches have focused on using 3T3 cells, HUH7 cells, and other prototypic cell lines which are easy to maintain and work with but are limited in their ability to recapitulate normal human cellular function and phenotype [2, 4, 5] . Consequently, the study of many pathogens and hostpathogen interactions has been more limited or constrained as the pathogen life cycle cannot reliably and robustly be reproduced in vitro in primary cells [3] .
Nowhere is this clearer than in hepatotropic infections such as in Hepatitis B Virus (HBV) or Hepatitis C virus (HCV) infection [5] . HBV as a prototypical hepatotropic viral pathogen is the most common viral hepatitis having infected over two billion people and chronically infecting more than 400 million worldwide, putting them at increased risk to develop cirrhosis and hepatocellular carcinoma [6, 7] . In the United States, over one million people have chronic hepatitis B viral infection [7] . Clinical therapy is targeted to the suppression of viral replication but the virus is able to persist in a nonreplicative covalently closed circular form called cccDNA, with the potential to reactivate upon immune suppression or with aging [6, 8] . As a consequence, the hepatitis B virus in chronic HBV infections is challenging to eradicate and cure is rare [6, 8] . The difficulty in the development of new HBV therapies results from the lack of good model systems due to the virus's narrow host range and cellular tropism for hepatocytes. As an example, despite the identification of HBV in 1968, the entry receptor (NTCP) for hepatitis B virus was only first identified in 2012 [9] .
Therefore, the use of more representative and functional cell types is required to better recapitulate the viral life cycle and host-virus interactions. The idea of cellular reprogramming in that one can convert the phenotype of a cell through genetic or cellular manipulation is an old one and originates as early as the 1950s with classic experiments using frog oocytes to reprogram adult nuclei to form whole embryos (leading to the development of somatic cell nuclear transfer) [10] . 
Using iPS-and iPS-Derived Hepatocyte-Like Cells as Models to Study Human Liver Disease iPS-Derived Hepatocyte-Like Cells as Models to Study Human Drug Metabolism and Cell Response
Although the focus of this review is on the applications of PSC-derived cells types to study infectious disease, iPSCs contain the genetic contributions of the donor and therefore provide an excellent opportunity to model human disease broadly and human liver disease specifically. iPSCs-and iPS-derived hepatocyte-like cells (iHLCs) offer multiple opportunities including hepatocyte-like cell generation for possible cell replacement therapy, disease modeling, drug modeling, as well as a variety of applications. While cell replacement therapy would address a significant clinical need [15] , this therapeutic goal is still far on the horizon, and thus the near-term potential of iHLCs may rest in applying them to serve as a platform for disease modeling and drug testing [17] . Genetic variation impacts cellular response and metabolism of various drugs. PSC-derived hepatocytes therefore can be used to model drug metabolism and production of daughter products and may help identify the production of clinically significant drug metabolites that may impede clinical trials and drug failures. Moreover, such approaches may help identify the impact that rare cytochrome P450 genotypes have on drug metabolism and help lead to drug (and thus patient) profiling of drugs before they reach the broader market. This approach could greatly impact the cost of drug development which currently is influenced by the attrition rate of tested compounds; for every drug that reaches the marketplace, 7500-10,000 molecules are tested in a preclinical setting [18] . More broadly, it is recognized that genetic variation greatly impacts the individual responses to drug treatment. PSC-derived hepatocytes would allow for the identification of the patient population subsets most likely to respond to various drug therapies in advance of actual drug treatment. Efforts to stratify patients based on genetic profiling are already being used in cancer therapy and are likely to extend to a variety of new and novel treatments in a revolution commonly called precision medicine [19] .
iPS-Derived Hepatocyte-Like Cells as Models to Study Human Liver Genetic Inborn Errors of Metabolism
As mentioned iPSC can be generated from a variety of donors and have been generated from patients with hepatocyte-based genetic inborn errors of metabolism or diseases. These diseases include A1AT deficiency [20] [21] [22] and demonstrated that iHLCs generated from these cell lines had a similar lipid profile, phenotype and defects to those described in the patient [23] . In all of these papers, it was demonstrated that the iHLCs recapitulate the disease phenotypes and represent an invaluable opportunity to study liver disease phenotypes in vitro thereby enabling disease study and drug development. One challenge present in all of these studies is that each patient derived iPSC cell line has a variety of genetic variants and/or mutations (outside of the evaluated and studied mutation) that may modify or impact disease phenotype. Reproducible differences in disease phenotypes may therefore be due to these genetic modifiers rather than primarily due to the disease mutation. Therefore, identifying appropriate controls is critical to evaluate observed phenotypes and traditionally gene repair has been used to produce these internal controls. Future studies may therefore be able to capitalize on the robustness of these platforms to identify the genetic and epigenetic modifiers that modulate disease phenotype.
Genome Engineering Approaches in Human iPSand Human iPS-Derived Hepatocyte-Like Cells
One significant advance outside of the stem cell community (which dovetails well in addressing the aforementioned concerns) and is rapidly impacting the scientific community is genome engineering; starting initially with zinc-finger nucleases [31], transcription activator-like effector nuclease [32] and now with the discovery and application of Cas9 endonuclease [33] . The RNA-guided CrispR (clustered regularly interspaced short palindrome repeats)-associated nuclease Cas9 offers targeted DNA binding (enabling DNA nicking/cleavage or transcriptional activation) at specific sites in the genome of mammalian cells [33, 34] . Native Cas9 is an endonuclease which can be targeted using a synthetic single-guide RNA (sgRNA) to specific genomic targets and induce DNA doublestrand breaks resulting in insertion/deletion (indel) mutations resulting in a frame-shift and subsequent allele loss [34] . The specificity of Cas9 is conferred by short guide sequences enabling the development of large libraries of guide sequences targeting the whole genome enabling genome-scale targeting and subsequent knockdown or targeted genome manipulation [34] . These approaches enable both genetic correction (in the case of cell lines generated from patients with specific mutations) or to generate cell lines with targeted mutations enabling cell lines with various mutations to be generated in a syngeneic background. This ''genome engineering'' technique was used to successfully correct point mutations in A1AT disease iPSCs [35] . Alternatively, the PCSK9 gene was targeted and mutated using CrispR-Cas9 in the mouse liver generating mice with an altered lipid profile mimicking the human disease phenotype or in humanized human liver chimeric mice [36, 37] . When taken together with the aforementioned work in iPSC generation, concern over adequate controls can be eliminated using genome engineering approaches in syngeneic genetic backgrounds with only the generated mutations then responsible for the observed phenotypes.
Summary
Pluripotent stem cell-derived hepatocyte-like cells represent a unique opportunity for both clinical and basic science translation and has the potential for translation as a cell replacement therapy, in disease modeling, drug modeling, as well as a variety of applications to model human liver disease.
iPS-Derived Hepatocyte-Like Cells as Models to Study Infectious Disease
The generation of iPSC and genome engineering technologies has revolutionized the ability to study and model the mechanisms of genetic diseases and are uniquely situated to study Curr Pathobiol Rep (2016) 
Human Liver Disease Epidemiology
Liver disease is an important clinical problem, impacting over 30 million Americans and 600 million people worldwide and is the 12 th leading cause of death in the United States, 7 th in Europe, and 16 th worldwide (Liver disease is responsible for over 30,000 deaths in the United States and 1 million deaths worldwide each year [49] ). Due to an aging population, liver morbidity has increased despite improved treatment tools. Long-term infection with the hepatitis C virus (HCV) is a significant cause of current worldwide liver morbidity and mortality, infecting 160-190 million people worldwide (approximately 3 % of the worldwide population) and puts these people at risk to develop liver injury including cirrhosis and hepatocellular carcinoma [50, 51]. Although HCV incidence has decreased significantly over the last 20 years, due to the long and often silent incubation period it is estimated that the number of undiagnosed individuals will continue to increase over the next decade. Unfortunately, an effective prophylactic HCV vaccine is not available. In contrast, several effective direct-acting antiviral drugs (DAAs) targeting HCV viral factors efficiently block HCV replication and result in a sustained virological response (viral cure) in over 90 percent of patients [52, 53] . However, due to the high cost of DAA treatment and the lack of a HCV vaccine, HCV eradication is going to be challenging and elusive particularly in the developing world [54, 55] .
Hepatitis C Virus Biology and Platform Development

HCV Description
HCV is a positive-sense single-stranded RNA virus of the Flaviviridae viral family (other family members include yellow fever, dengue fever, and Zika virus) that infects patients via direct blood contact (i.e., contaminated blood or blood supplies or intravenous drug use) [50, 51] . It primarily targets primary hepatocytes [51] . HCV strains are classified into seven genotypes based on sequence analysis with genotypes 1 and 3 the most prevalent worldwide [56] . Of patients infected with the virus, approximately threequarters go on to develop a chronic infection [52] . The HCV virus has a very specific species tropism (i.e., human and chimpanzee) and cell tropism (i.e., hepatocyte) that initially hampered HCV research [57] . HCV was first discovered in 1989 [58] but the lack of a cell culture system (as well as a virus capable of launching HCV infection) significantly hampered the study of HCV [59] . Recognition that the 5' or 3' end of the HCV genome may be incorrect or incomplete led to the discovery that the HCV consensus genomes lacked part of the 3' NTR [60] [61] [62] [63] . Consensus sequences were used to correct errors or deleterious mutations present in the HCV genome. Combining both of these approaches led to the development of HCV clones that were infectious in vivo in chimpanzees but for reasons that remained unclear at the time did not lead to the production of infectious viral particles in vitro [64, 65] . Many attempts to detect viral replication led to the realization that it also would be impossible to detect the low level of HCV replication (if present) in the background of the large amount of input HCV RNA used to initiate infection. Therefore, different systems were developed that would enable the detection of viral replication.
Development of the Subgenomic Replicon and HCV Permissive Cell Lines
Inspired by work in other positive strand RNA viruses that showed that the structural proteins are dispensable for RNA replication [66] , the minimal set of HCV proteins required to initiate and maintain HCV replication was determined and subgenomic replicons containing luciferase reporters or antibiotic selection markers were created, establishing for the first time a cell-based model for HCV replication [67] [68] [69] . Over time, adaptive mutations were selected during viral replication leading to the emergence of HCV variants with higher replicative capability [70] [71] [72] . Moreover, isolation and treatment (with interferon or drugs targeting HCV replication) of selected replicon cells led to ''cured cells'' along with the development of cells that were more highly permissive than the parental cells (i.e., leading to the development of permissive clones such as Huh-7.5 cells) [73] . Subgenomic replicons have been reported for most HCV genotypes and significantly contributed to the development of direct-acting antivirals. After the creation of efficiently replicative subgenomic clones, it was hoped that a permissive cell culture system would be easily created. With that in mind, genomic replicons encoding the complete HCV polyprotein were constructed [74] . These genomic replicons were capable of replicating in Huh7 parent and daughter cell lines but could not support virus particle production [74, 75] . Perturbation of genomic replicon system or selection markers did not lead to improved results, and therefore, it was believed that either the Huh7 cell line could not support robust virus production or that mutations in the HCV genome were not supporting adequate viral replication and virion production simultaneously [76] .
Discovery of the JFH-1 Isolate and Cell Culture Production of HCV
The discovery of the JFH-1 isolate [77] coupled with the development of the huh-7.5 cell line (clone of huh7 which has a defect in Rig-I which mutes the antiviral response to infection) led to the production of high titers of infectious HCV virions (cell culture derived HCV or HCVcc) [78] . Despite these significant advances, HCV replication and viral infection have largely been studied in Huh-7 cell lines or its daughter lines. While these hepatoma cell lines now support high levels of HCV viral replication and/or virion production, the interpretation of the impacts HCV has on hepatocyte biology and that the hepatocyte has on the HCV virus is limited given the constraints of hepatoma cell lines. These limitations include the significant differences in RNA and protein expression and production between hepatoma cell lines and primary human hepatocytes. Moreover, these cell lines are rapidly proliferative and are not polarized in vitro which stands in stark contrast to primary human hepatocytes phenotype and function. Moreover, these hepatoma cell lines (i.e., Huh7.5) are known to have significant defects in the antiviral response [3, 79, 80] . Therefore, these limitations can be overcome by using primary human hepatocytes and several reports have shown that primary human hepatocytes can support HCV infection in vitro [81, 82] . Unfortunately, there are several limitations using primary human hepatocytes including the difficulty and variability in hepatocyte sourcing as well as the difficulty in maintaining the differentiated hepatocyte state in vitro [83] . Moreover, in several studies, only low-level replication and virion production were demonstrated. Several platforms that enable the enhanced survival and differentiated function of primary human hepatocytes have been developed [84] [85] [86] . Further improvements in primary human hepatocyte were realized when micropatterned co-cultures of primary human hepatocytes organized on collagen-coated islands along with fibroblasts maintain hepatocyte function [85] , HCV permissiveness, and enabled HCV infection, viral replication, along with the upregulation of the antiviral response [87] . 
Creation of Human Liver Chimeric Mice Using iHLCs Enables the Study of HCV Infection in Vivo
Engraftment of iHLCs in vivo to produce human liver chimeric mouse models has been fraught with low efficiencies [15, 94] . In contrast using an optimized hepatocyte differentiation protocol and the MUP-uPA/SCID/bg model, iHLCs were able to engraft and repopulate a liver injury model to produce a human liver chimeric mouse with high levels of human chimerism [90 • ]. Subsequent infection of these engrafted human liver iHLC chimeric mice with HCV noted that low-dose HCV inoculations were unsuccessful in producing detectable infections while high-dose inoculations (1,000 CID50 per mouse) launched productive and chronic HCV infection [90 • ]. Chimeric mice were capable of supporting infections of HCV of varying genotypes including genotype 1a, 1b, or 3a. At least 5 % human iHLC chimerism (*450 mcg/mL) was necessary to support HCV infection [90 • ].
Limitation of iPS-Derived Hepatocyte-Like Cells to Study Infectious Disease
iHLCs do have some limitations which are pertinent to understand for the scope of experimental study. iHLC generation varies from cell line to cell line with timing or cytokine concentrations necessary for hepatocyte differentiation somewhat variant between pluripotent cell lines. Moreover, the phenotype and function of iHLCs while robust have been shown to closer to that of a fetal hepatocyte rather than an adult hepatocyte [15, 16] . Although this is a challenge particularly in the context of drug metabolism studies, iHLCs have been shown to be a robust tool for the study of a variety of hepatotropic pathogen including HCV infection. In particular, they have been used to dissect out the role of genetic variations in HCV permissiveness, respond to infection with upregulation of interferon-stimulated genes, and have enabled the study of several HCV genotype variants.
Summary
Pluripotent stem cell-derived hepatocyte-like cells have revolutionized the ability to study host-pathogen interactions, infectious disease pathogenesis, and genetic susceptibility or resistance to infection. HCV is a hepatotropic pathogen, which has been closely studied and over time a variety of standardized tools were established which resulted in a good understanding of its viral life cycle and ultimate cure. An understanding of the history of the study of the HCV virus serves as a great background for understanding study in the infectious disease and virology communities.
Overall Conclusions
Liver disease is an important global problem and is responsible for 1 million deaths worldwide each year. Infectious disease is a major cause of liver disease specifically and overall is even a greater cause of patient morbidity and mortality responsible for over one-fifth of deaths worldwide. Tools to study human liver disease and infectious disease have been lacking which has significantly hampered the study of liver disease generally and hepatotropic pathogens more specifically. Cellular reprogramming technologies which have culminated in the creation of iPSC represent an unprecedented opportunity to study and treat a variety of human diseases. Pluripotent stem cells are renewable, can be derived from a single donor, and can be efficiently and reproducibly differentiated towards many cell types including ectodermal-, endodermal-, and mesodermal-derived lineages.
Traditional studies have been dependent on the use of cell lines which only poorly mimic the cell type of interest if at all and consequently resulted in our limited understanding of key issues in infectious disease and liver biology; (1) What is the impact that a hepatotropic pathogen has on hepatocyte biology, (2) What is the impact that the hepatocyte has on hepatotropic pathogens, (3) How does chronic infection change the long-term behavior of infected hepatocytes. Although this is a brief list, these are fundamental questions that have import beyond the laboratory but have significant clinical impact as it is currently unclear (in the case of HCV) whether patient cure eliminates the complete risks and sequelae of HCV infection. Such questions and concerns will be only addressed with more relevant in vitro and in vivo models of HCV infection.
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